Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.
A 79-year-old woman presents with left anterior knee pain after a fall.
Inflammatory bowel disease (IBD) is associated with diverse pulmonary manifestations, and it remains difficult to determine whether those are secondary to medications or the underlying process. Little is known about the clinical course or disease severity of these patients. Our objective was to describe the clinical characteristics and disease course of lung disease among patients with IBD seen at our Institution. METHODS: We performed a retrospective cohort study of IBD patients at the University of Florida between 2012 and 2019. We included patients with biopsy proven diagnosis of IBD or by consensus from our gastroenterology department. We collected demographic, clinical, physiological, and radiographic information. RESULTS: 319 patients were included in the analysis. 75% of patients had a pulmonary abnormality either on pulmonary functions tests or chest imaging. The most frequent comorbidity was smoking related lung disease. 6% had parenchymal lung disease, 8% had airway disease, 16% had pulmonary nodules, 17% pulmonary vascular disease (including pulmonary hypertension and pulmonary embolism), and 28% had other pulmonary manifestations. CONCLUSIONS: Pulmonary manifestations of IBD are increasingly recognized. We present a large cohort characterizing the pulmonary manifestations among IBD patients and their clinical course. CLINICAL IMPLICATIONS: Larger studies are needed to provide information on the prevalence and clinical progression of pulmonary disease in the IBD population. Further work to identify therapeutic options for this group is needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.